Leukemia News

In this video, Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute, spoke with Healio about a study presented at ASCO 2021 that showed high doses of aspacytarabine are safe to use in older patients with acute myeloid leukemia.

In this video Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana-Farber Institute, spoke with Healio about a study that showed a three-dose schedule of ponatinib with a higher initial dose was superior to other dosing methods for patients with chronic myeloid leukemia.

The FDA granted orphan drug designation to CTD401, a chimeric antigen receptor T-cell therapy for the treatment of T-cell acute lymphoblastic leukemia, according to the agent’s manufacturer.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the clinical implications of the BEAT-AML trial and genetic testing in AML.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the transition of newer agents into clinical practice.

Healio spoke with Jonathan M. Gerber, MD, chief of hematology-oncology and medical director of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, Eleanor Eustis Farrington Chair in Cancer Research and HemOnc Today Editorial Board member, about FDA approvals, the transition of newer agents into clinical practice and breakthroughs in therapy that he hopes to see in the future in this video series.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about breakthroughs in therapy that he hopes to see in the future.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the underrecognized burden of high treatment costs in AML.

Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.

Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results.